ニュース
12月21日 業績を更新しました
原著論文(英文)
2011年
1. Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S.
Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
J Thorac Oncol Nov 15. [Epub ahead of print].
2. Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S.
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Clin Cancer Res 2011 17;2260-9.
3. Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, Tacheuchi S, Mouri H, Yamashita K, Ohtsubo K, Yano S.
The EGFR ligands amphiregulin and heparin-binding EGF-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.
Clin Cancer Res 2011;17:3619-30.
4. Li Q, Wang W, Yamada T, Matsumoto K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T,Yasumoto K,Yano S.
Pleural mesothelioma instigates tumor associated fibroblasts to promote progression via malignant cytokine network.
Am J Pathol 2011; 179:1483-93.
5. Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto U, Yasumoto Y, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M.
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
J Thorac Oncol 2011;6:2011-7.
6. Yamada T, Bando H, Takeuchi S, Kita K, Li Q, Wang W, Akinaga S, Nishioka Y, Sone S, Yano S.
Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2 expressing small cell lung cancer.
Cancer Sci 2011; 102:2157-63.
7. Tomimoto H, Hanibuchi M, Ogushi F, Okano Y, Shinohara T, Doi H, Yamamoto A, Takeuchi E, Yamamoto A, Azuma M, Tada H, Kanematsu T, Kakiuchi S, Goto H, Yano S, Nishioka Y, Sone S.
A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Oncology Letter in press.
8. Sano T, Takahashi M, Nozaki T, Takahashi Y, Tamura M, Nashimoto M.
Expanding the utility of heptamer-type sgRNA for TRUE gene silencing.
Biochem Biophys Res Commun 2011; 416:427-32.
9. Tanaka S, Nakada M, Hayashi Y, Nakada S, Kitamura-Sawada S, Furuyama N, Suzuki T, Kamide T, Hayashi Y, Yano S, Hamada JI.
Epithelioid glioblastoma changed to typical glioblastoma -the methylation status of MGMT promoter and 5-ALA fluorescence -.
Brain Tumor Pathol 2011;28:59-64.
10. Tanaka H, Kimura T, Kudoh S, Mitsuoka S, Watanabe T, Suzumura T, Tachibana K, Noguchi M, Yano S, Hirata K.
Reaction of plasma hepatocyte growth factor level in lung cancer patients treated with EGFR-TKIs.
Int J Cancer 2011 126:1410-6.
11. Shiirevnyamba A, Takahashi T, Shan H, Ogawa H, Yano S, Kanayama H, Izumi K, Uehara H.
Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts.
Br J Cancer 2011;104:505-13.
12. Ogino H, Hanibuchi M, Kakiuchi S, Trung Van The, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S.
E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.
Mol Cancer Ther 2011;10:1218-28.
研究業績へ
2011年
1. Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S.
Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
J Thorac Oncol Nov 15. [Epub ahead of print].
2. Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S.
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Clin Cancer Res 2011 17;2260-9.
3. Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, Tacheuchi S, Mouri H, Yamashita K, Ohtsubo K, Yano S.
The EGFR ligands amphiregulin and heparin-binding EGF-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.
Clin Cancer Res 2011;17:3619-30.
4. Li Q, Wang W, Yamada T, Matsumoto K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T,Yasumoto K,Yano S.
Pleural mesothelioma instigates tumor associated fibroblasts to promote progression via malignant cytokine network.
Am J Pathol 2011; 179:1483-93.
5. Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto U, Yasumoto Y, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M.
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
J Thorac Oncol 2011;6:2011-7.
6. Yamada T, Bando H, Takeuchi S, Kita K, Li Q, Wang W, Akinaga S, Nishioka Y, Sone S, Yano S.
Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2 expressing small cell lung cancer.
Cancer Sci 2011; 102:2157-63.
7. Tomimoto H, Hanibuchi M, Ogushi F, Okano Y, Shinohara T, Doi H, Yamamoto A, Takeuchi E, Yamamoto A, Azuma M, Tada H, Kanematsu T, Kakiuchi S, Goto H, Yano S, Nishioka Y, Sone S.
A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Oncology Letter in press.
8. Sano T, Takahashi M, Nozaki T, Takahashi Y, Tamura M, Nashimoto M.
Expanding the utility of heptamer-type sgRNA for TRUE gene silencing.
Biochem Biophys Res Commun 2011; 416:427-32.
9. Tanaka S, Nakada M, Hayashi Y, Nakada S, Kitamura-Sawada S, Furuyama N, Suzuki T, Kamide T, Hayashi Y, Yano S, Hamada JI.
Epithelioid glioblastoma changed to typical glioblastoma -the methylation status of MGMT promoter and 5-ALA fluorescence -.
Brain Tumor Pathol 2011;28:59-64.
10. Tanaka H, Kimura T, Kudoh S, Mitsuoka S, Watanabe T, Suzumura T, Tachibana K, Noguchi M, Yano S, Hirata K.
Reaction of plasma hepatocyte growth factor level in lung cancer patients treated with EGFR-TKIs.
Int J Cancer 2011 126:1410-6.
11. Shiirevnyamba A, Takahashi T, Shan H, Ogawa H, Yano S, Kanayama H, Izumi K, Uehara H.
Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts.
Br J Cancer 2011;104:505-13.
12. Ogino H, Hanibuchi M, Kakiuchi S, Trung Van The, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S.
E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.
Mol Cancer Ther 2011;10:1218-28.
研究業績へ
